We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABMD - Replacement Heart System
ABMD 267.68+0.6%2:50 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Lynn5/9/2018 6:13:27 PM
1 Recommendation

Recommended By

   of 147
Abiomed Climbs to Record After Fiscal Q4 EPS, Rervenue Beat Analyst Estimates 12:26 PM ET, 05/03/2018 - MT Newswires12:26 PM EDT, 05/03/2018 (MT Newswires) -- Abiomed (ABMD) shares rose 11% to a record after reporting fiscal Q4 EPS of $0.80 compared with $0.33 a year earlier, beating the $0.66 average estimate of analysts in a Capital IQ poll.

The new 52-week range is $123.60 to $338.69.

Revenue was $174.4 million, an increase of 40% from $124.7 million a year earlier. That exceeded the $164.3 million analyst consensus.

The company sees total revenue in the 2019 fiscal year to be in the range of $740 million to $770 million, an increase of 25% to 30% over the previous fiscal year. It sees GAAP operating margin in the range of 28% to 30%.

Closing price: 358.16 Change +10.78 (+3.1%)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext